TSHA Key Statistics, Chart & Performance
The current stock price of TSHA is 4.95 USD. In the past month the price decreased by -12.5%. In the past year, price increased by 229.41%.
TSHA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to TSHA. When comparing the yearly performance of all stocks, TSHA is one of the better performing stocks in the market, outperforming 97.7% of all stocks.
TSHA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TSHA. The financial health of TSHA is average, but there are quite some concerns on its profitability.
TSHA Financial Highlights
Over the last trailing twelve months TSHA reported a non-GAAP Earnings per Share(EPS) of -0.33. The EPS decreased by -152.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.57% | ||
| ROE | -45.63% | ||
| Debt/Equity | 0.23 |
TSHA Forecast & Estimates
20 analysts have analysed TSHA and the average price target is 10.78 USD. This implies a price increase of 117.83% is expected in the next year compared to the current price of 4.95.
For the next year, analysts expect an EPS growth of -2.89% and a revenue growth -20.9% for TSHA
TSHA Ownership
TSHA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.95 | 383.34B | ||
| AMGN | AMGEN INC | 15.1 | 177.86B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 151.26B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.22 | 111.07B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.49 | 78.03B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 703.63 | 47.41B | ||
| INSM | INSMED INC | N/A | 34.00B | ||
| NTRA | NATERA INC | N/A | 33.25B | ||
| BIIB | BIOGEN INC | 10.06 | 24.71B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.75B | ||
| INCY | INCYTE CORP | 16.34 | 20.59B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.84 | 20.28B |
Related stock screener links
About TSHA
Company Profile
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. The company is headquartered in Dallas, Texas and currently employs 73 full-time employees. The company went IPO on 2020-09-24. The Company’s lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The firm is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. The company has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). TSHA-105 is a gene replacement therapy in development for the treatment of SLC13A5 deficiency, a rare autosomal recessive epileptic encephalopathy.
Company Info
TAYSHA GENE THERAPIES INC
3000 Pegasus Park Drive, Suite 1430
Dallas TEXAS 75247 US
CEO: RA Session
Employees: 73
Phone: 12146120000
TAYSHA GENE THERAPIES INC / TSHA FAQ
What does TAYSHA GENE THERAPIES INC do?
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. The company is headquartered in Dallas, Texas and currently employs 73 full-time employees. The company went IPO on 2020-09-24. The Company’s lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The firm is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. The company has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). TSHA-105 is a gene replacement therapy in development for the treatment of SLC13A5 deficiency, a rare autosomal recessive epileptic encephalopathy.
Can you provide the latest stock price for TAYSHA GENE THERAPIES INC?
The current stock price of TSHA is 4.95 USD. The price decreased by -1.79% in the last trading session.
Does TSHA stock pay dividends?
TSHA does not pay a dividend.
What is the ChartMill technical and fundamental rating of TSHA stock?
TSHA has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is TAYSHA GENE THERAPIES INC (TSHA) stock traded?
TSHA stock is listed on the Nasdaq exchange.
Can you provide the market cap for TAYSHA GENE THERAPIES INC?
TAYSHA GENE THERAPIES INC (TSHA) has a market capitalization of 1.36B USD. This makes TSHA a Small Cap stock.
What is the outstanding short interest for TAYSHA GENE THERAPIES INC?
The outstanding short interest for TAYSHA GENE THERAPIES INC (TSHA) is 19.94% of its float.